Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer

18 Oct 2014

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 25458954
DOI: 10.1016/j.canlet.2014.10.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancerPMID 25458954Read ↗

Synergistic Effect of Epigenetic Modulator Decitabine and Metformin in the Battle Against Gastric Cancer: A Potential Therapeutic StrategySemantic proximity Read ↗

Combating pancreatic cancer chemoresistance by triggering multiple cell death pathwaysSemantic proximity Read ↗

MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.Semantic proximity Read ↗

Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerationsSemantic proximity Read ↗

Selective activation of tumor-suppressive MAPKP signaling pathway by triptonide effectively inhibits pancreatic cancer cell tumorigenicity and tumor growthSemantic proximity Read ↗

Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer.Semantic proximity Read ↗

MiR-377 inhibits the proliferation of pancreatic cancer by targeting Pim-3Semantic proximity Read ↗

Rationale and clinical use of multitargeting anticancer agentsSemantic proximity Read ↗

Recent Advances in Synergistic Antitumor Effects Exploited from the Inhibition of Ataxia Telangiectasia and RAD3-Related Protein Kinase (ATR)Semantic proximity Read ↗

Targeting PI3K Signaling in Combination Cancer Therapy.Semantic proximity Read ↗

A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.Semantic proximity Read ↗

The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Enhances the Antitumoral Activity of Gemcitabine in Human Pancreatic Cancer Cell LinesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.